- Technology Management
- For Industry - Technology Available for Licensing
- Contact Technology Management
- old pages
- A Modern Approach to Wing Warp for Aircraft Control
- Treatment Of Liver Fibrosis Following Hepatic Injury By Selective Killing Of Activated Liver Stellate Cells
- Compositions and Methods for Treating and Diagnosing Hepatoma
- Vaccine Compositions and Methods That Increase Safety of Anti-Viral Vaccination Without Loss of Efficacy
- Automatic Pressure-Locking Valve Prevents CSF Loss and Herniation During Lumbar Puncture When Intracranial Pressure Is Elevated.
- Immortal Differentiated Type II Lung Epithelial Cell Line (T7)
- Human A Rapid, Reliable Bedside Diagnostic Method For Accurately Determining Feeding Tube Placement In Respiratory Tract, Stomach, Or Small Bowel Of Patients Prior to Enteral Nutrient Administration.
- Human Natural Killer Cell Line - NK 3.3:
- Factor IXa Protease Helix-330 (Region 1)
- In Vitro Method for Concerted Integration of Donor DNA Molecules Into Target DNA Using Retroviral Integrase and a Procedure for Evaluation of Donor DNA Integration.
- SRCAP: A Novel Transcription Protein Having Therapeutic Target and Diagnostic Target Product Development Potential.
- C-Terminal Binding Protein Interacting Protein (CtIP):
- Novel Anti-Coagulation Therapeutics: Agents That Effectively Inhibit Binding of Factor VIIIa (Region 3) With Factor IXa (Region 2) Without Activating Factor X.
- Genetically Modified Activated Protein C with Reduced Anticoagulant Properties
- C22: A Conditionally Immortalized Mouse Clara Cell Line
C-Terminal Binding Protein Interacting Protein (CtIP):
A Novel Modulator of Cellular Neoplasia And A Target Useful For Assessing Malignancy of Tumor Cells and Screening of Anti-Cancer Drugs.
Inventor: Dr. Govindaswamy Chinnadurai
A novel human protein, designated as CtIP (C-terminal binding protein interacting protein), which binds to the cellular C-terminal binding protein (CtBP) has been isolated, sequenced and characterized. The human CtIP protein contains the same five amino acid motif (PLDLS) that is present in adenovirus E1A proteins which bind to human CtBP.The interaction of adenovirus E1A proteins with CtBP leads to suppression of tumorigenesis and tumor metastasis of cells transformed with E1A and activated T24 Ras oncogene. Deletion of the PLDLS motif in CtIP abolishes its ability to bind to CtBP. CtIP also interacts with tumor suppressor proteins BRCA-1 and the pRb family of proteins.
Various CtIP-related laboratory reagents and methods are available for use in R&D directed to the discovery and development cancer diagnostic tests and anti-cancer therapeutic agents targeted to modulation of the CtIP-CtBP interaction, including: (i) monoclonal and polyclonal antibodies directed against human CtBP and human CtIP, (ii) a transformed cell line expressing human CtIP, (iii) isolated and purified human CtIP polynucleotides and polypeptides (and fragments thereof), (iv) cDNA clone CtIP, (v) a method for determining malignancy of a cell in a patient, (vi) an immunoassay for CtIP, (vii) a method for detecting CtIP mRNA, (viii) a method for screening inhibitors of neoplasia, and (ix) a method for evaluating levels of cellular expression of the CtIP gene and quantitation of CtIP protein activity.
Application: The human CtIP protein described here relates to methods and compositions useful for the development of in vitro assays for diagnosis of tumor malignancy as well as to compositions which may be useful for suppressing tumor growth and metastasis in patients.
Keywords: neoplasia, cancer diagnosis, angiogenesis, breast cancer, tumor specific antigen, oncogene, tumor, CtIP assay, CBP
US Patent No.: 5,773,599 (Date: June 30, 1998);
PCT/US98/26505 WO 99/29334 (Date: 17 June 1999);
US Serial No. 09/581,094 (Filed: Aug. 18, 2000) - US National Phase of PCT/US98/26505.
License: Collaborative research and licensing opportunities are available.
Reference Number: SLU-1004